Logo image of BDSX

BIODESIX INC (BDSX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BDSX - US09075X2071 - Common Stock

6.72 USD
-0.14 (-2.04%)
Last: 12/30/2025, 8:07:18 PM
6.51 USD
-0.21 (-3.12%)
Pre-Market: 12/31/2025, 5:18:19 AM
Fundamental Rating

3

BDSX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 101 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of BDSX have multiple concerns. BDSX shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BDSX had negative earnings in the past year.
BDSX had a negative operating cash flow in the past year.
In the past 5 years BDSX always reported negative net income.
In the past 5 years BDSX always reported negative operating cash flow.
BDSX Yearly Net Income VS EBIT VS OCF VS FCFBDSX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

The Return On Assets of BDSX (-44.56%) is worse than 89.11% of its industry peers.
Industry RankSector Rank
ROA -44.56%
ROE N/A
ROIC N/A
ROA(3y)-55.74%
ROA(5y)-49.96%
ROE(3y)-553.97%
ROE(5y)-391.42%
ROIC(3y)N/A
ROIC(5y)N/A
BDSX Yearly ROA, ROE, ROICBDSX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

1.3 Margins

BDSX has a better Gross Margin (79.82%) than 94.06% of its industry peers.
In the last couple of years the Gross Margin of BDSX has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for BDSX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 79.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.1%
GM growth 5Y0.76%
BDSX Yearly Profit, Operating, Gross MarginsBDSX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

2

2. Health

2.1 Basic Checks

BDSX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BDSX has more shares outstanding
The number of shares outstanding for BDSX has been increased compared to 5 years ago.
BDSX has a worse debt/assets ratio than last year.
BDSX Yearly Shares OutstandingBDSX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
BDSX Yearly Total Debt VS Total AssetsBDSX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -7.53, we must say that BDSX is in the distress zone and has some risk of bankruptcy.
BDSX has a Altman-Z score of -7.53. This is amonst the worse of the industry: BDSX underperforms 92.08% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -7.53
ROIC/WACCN/A
WACC13.08%
BDSX Yearly LT Debt VS Equity VS FCFBDSX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

2.3 Liquidity

A Current Ratio of 1.84 indicates that BDSX should not have too much problems paying its short term obligations.
BDSX's Current ratio of 1.84 is fine compared to the rest of the industry. BDSX outperforms 72.28% of its industry peers.
A Quick Ratio of 1.84 indicates that BDSX should not have too much problems paying its short term obligations.
BDSX has a Quick ratio of 1.84. This is in the better half of the industry: BDSX outperforms 76.24% of its industry peers.
Industry RankSector Rank
Current Ratio 1.84
Quick Ratio 1.84
BDSX Yearly Current Assets VS Current LiabilitesBDSX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

7

3. Growth

3.1 Past

BDSX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.72%, which is quite impressive.
Looking at the last year, BDSX shows a very strong growth in Revenue. The Revenue has grown by 22.29%.
BDSX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 23.78% yearly.
EPS 1Y (TTM)28.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.14%
Revenue 1Y (TTM)22.29%
Revenue growth 3Y9.37%
Revenue growth 5Y23.78%
Sales Q2Q%19.93%

3.2 Future

The Earnings Per Share is expected to grow by 20.46% on average over the next years. This is a very strong growth
Based on estimates for the next years, BDSX will show a very strong growth in Revenue. The Revenue will grow by 21.31% on average per year.
EPS Next Y17.09%
EPS Next 2Y24.05%
EPS Next 3Y20.46%
EPS Next 5YN/A
Revenue Next Year19.38%
Revenue Next 2Y22.18%
Revenue Next 3Y21.31%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
BDSX Yearly Revenue VS EstimatesBDSX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
BDSX Yearly EPS VS EstimatesBDSX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BDSX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BDSX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BDSX Price Earnings VS Forward Price EarningsBDSX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BDSX Per share dataBDSX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

A more expensive valuation may be justified as BDSX's earnings are expected to grow with 20.46% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.05%
EPS Next 3Y20.46%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BDSX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

BIODESIX INC

NASDAQ:BDSX (12/30/2025, 8:07:18 PM)

Premarket: 6.51 -0.21 (-3.12%)

6.72

-0.14 (-2.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-03 2025-11-03/amc
Earnings (Next)03-02 2026-03-02/bmo
Inst Owners16.71%
Inst Owner Change-95.98%
Ins Owners23.96%
Ins Owner Change1.72%
Market Cap53.49M
Revenue(TTM)80.17M
Net Income(TTM)-39.53M
Analysts80
Price Target33.15 (393.3%)
Short Float %2.26%
Short Ratio0.5
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.12%
Min EPS beat(2)-14.78%
Max EPS beat(2)21.02%
EPS beat(4)2
Avg EPS beat(4)0.67%
Min EPS beat(4)-15.34%
Max EPS beat(4)21.02%
EPS beat(8)6
Avg EPS beat(8)4.87%
EPS beat(12)9
Avg EPS beat(12)3.64%
EPS beat(16)11
Avg EPS beat(16)2.38%
Revenue beat(2)2
Avg Revenue beat(2)4.02%
Min Revenue beat(2)1.75%
Max Revenue beat(2)6.29%
Revenue beat(4)3
Avg Revenue beat(4)-0.19%
Min Revenue beat(4)-9.55%
Max Revenue beat(4)6.29%
Revenue beat(8)5
Avg Revenue beat(8)-0.27%
Revenue beat(12)6
Avg Revenue beat(12)-1.75%
Revenue beat(16)8
Avg Revenue beat(16)0.07%
PT rev (1m)0%
PT rev (3m)1757.14%
EPS NQ rev (1m)17.05%
EPS NQ rev (3m)-1559.09%
EPS NY rev (1m)-5.37%
EPS NY rev (3m)-0.71%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.33%
Revenue NY rev (1m)1.44%
Revenue NY rev (3m)1.65%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.67
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.56
EYN/A
EPS(NY)-3.23
Fwd EYN/A
FCF(TTM)-3.67
FCFYN/A
OCF(TTM)-3.52
OCFYN/A
SpS10.07
BVpS-0.22
TBVpS-2.65
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -44.56%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 79.82%
FCFM N/A
ROA(3y)-55.74%
ROA(5y)-49.96%
ROE(3y)-553.97%
ROE(5y)-391.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.1%
GM growth 5Y0.76%
F-Score3
Asset Turnover0.9
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20.57%
Cap/Sales 1.47%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.84
Quick Ratio 1.84
Altman-Z -7.53
F-Score3
WACC13.08%
ROIC/WACCN/A
Cap/Depr(3y)283.54%
Cap/Depr(5y)201.2%
Cap/Sales(3y)20.35%
Cap/Sales(5y)14.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.14%
EPS Next Y17.09%
EPS Next 2Y24.05%
EPS Next 3Y20.46%
EPS Next 5YN/A
Revenue 1Y (TTM)22.29%
Revenue growth 3Y9.37%
Revenue growth 5Y23.78%
Sales Q2Q%19.93%
Revenue Next Year19.38%
Revenue Next 2Y22.18%
Revenue Next 3Y21.31%
Revenue Next 5YN/A
EBIT growth 1Y6.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.4%
EBIT Next 3Y26.05%
EBIT Next 5YN/A
FCF growth 1Y34.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.44%
OCF growth 3YN/A
OCF growth 5YN/A

BIODESIX INC / BDSX FAQ

Can you provide the ChartMill fundamental rating for BIODESIX INC?

ChartMill assigns a fundamental rating of 3 / 10 to BDSX.


Can you provide the valuation status for BIODESIX INC?

ChartMill assigns a valuation rating of 1 / 10 to BIODESIX INC (BDSX). This can be considered as Overvalued.


Can you provide the profitability details for BIODESIX INC?

BIODESIX INC (BDSX) has a profitability rating of 1 / 10.


Can you provide the financial health for BDSX stock?

The financial health rating of BIODESIX INC (BDSX) is 2 / 10.


What is the expected EPS growth for BIODESIX INC (BDSX) stock?

The Earnings per Share (EPS) of BIODESIX INC (BDSX) is expected to grow by 17.09% in the next year.